Engelsk titel: Fibrosis indexes reduce the need of liver biopsy in chronic hepatitis C
Läs online
Författare:
Björklund J
;
Aleman S
;
Weiland O
Email: ola.weiland@ki.se
Språk: Swe
Antal referenser: 15
Dokumenttyp:
Artikel
UI-nummer: 09041505
Sammanfattning
Liver biopsy is the golden standard to assess liver fibrosis in hepatitis C (HCV) infection. This invasive method is however associated with complications, which in few cases may be fatal.
We have evaluated simple fibrosis indexes, APRI, GUCI and FIB-4, based on chemical and hematological routine analyses among 173 patients with chronic HCV infection who had had a liver biopsy. These indexes could predict significant fibrosis, defined as stadium 3/4, with high accuracy. GUCI score with cut-off on 1,11 was the overall best index with a PPV of 85%, a NPV of 78%, and sensitivity and specificity of 67% and 91%, respectively.
The GUCI score may be used clinically to assess liver fibrosis in HCV infected patients to predict significant fibrosis. In the future, this score could be used in combination with Fibroscan, an ultrasound based method to measure liver stiffness, to replace liver biopsies in majority of patients with significant fibrosis.